Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma

Longitudinal data analysis using generalized linear models

LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197

On the origin of cancer cells

Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064

The 2015 World Health Organization Classification of Lung Tumors

Travis, W. D., Brambilla, E. M., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Đačić, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,532

Benefits and Harms of CT Screening for Lung Cancer

Bach, P. B., Mirkin, J. N., Oliver, T. K., Azzoli, C. G., Berry, D. A., Brawley, O. W., Byers, T., Colditz, G. A., Gould, M. K., Jett, J. R., et al. (2012) · JAMA · doi:10.1001/jama.2012.5521 · Cited by 1,237

Oxygen sensing and molecular adaptation to hypoxia

Bunn, H. F., & Poyton, R. Ο. (1996) · Physiological Reviews · doi:10.1152/physrev.1996.76.3.839 · Cited by 1,185

AMIDE: A Free Software Tool for Multimodality Medical Image Analysis

Loening, A. M., & Gambhir, S. S. (2003) · Molecular Imaging · doi:10.1162/153535003322556877 · Cited by 967

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873

Regulation of glut1 mRNA by Hypoxia-inducible Factor-1

Chen, C., Pore, N., Behrooz, A., Ismail‐Beigi, F., & Maity, A. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 769

SGLT2 Inhibitors in Combination Therapies for Tumors: A Novel Approach to Synergistic Treatment Strategies

Su, H., Li, X., Wang, S., Yang, X., Jiang, L., Luo, H., Li, Y., Zhou, J., Huang, Y., & Li, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s556231 · Cited by 6

Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer

Saggese, P., Martínez, C. J., Tran, L. M., Lim, R. J., Dumitras, C., Grogan, T., Elashoff, D. A., Salehi‐Rad, R., Dubinett, S. M., Liu, B., et al. (2021) · Cancers · doi:10.3390/cancers13143595 · Cited by 6

Comparison of the In Vitro Photodynamic Activity of the C1α and C1β Anomers of a Glucosylated Boron Dipyrromethene

Xiong, J., Yeung, K., Wong, C. T. T., Fong, W., & Ng, D. K. P. (2022) · Colorants · doi:10.3390/colorants1020012 · Cited by 6

Expression and Predictive Significance of FHL1 and SLIT3 in Surgically Resected Lung Adenocarcinoma

Song, J., Liang, K., Wei, T., Li, L., Huang, Z., Chen, G., Mao, N., & Yang, J. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230208124028 · Cited by 6

Cancer biology in diabetes update: Focusing on antidiabetic drugs

Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8

Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures

Chen, H., Zhang, M., Li, R., Liu, T., Li, J.-P., & Qu, Y.-Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645482 · Cited by 6

Preclinical Evaluation of Novel SGLT2-Targeted Near-Infrared Optical Imaging Agent for Early-Stage Pulmonary Adenocarcinoma

Welch, K. O., McGovern, K. A., Chen, L., Krouse, R., Guo, K., Huang, J. J., Brown, M., Mlakar, J., Bandi, V., Holt, D. E., et al. (2025) · Molecular Imaging and Biology · doi:10.1007/s11307-025-02029-w · Cited by 5

Diabetes and cancer: glucose control impact on survival and tumor outcomes

Ruggeri, R. M., Grossrubatscher, E. M., Arrivi, G., Ciocca, E., Filice, A., Golisano, B., Mazzilli, R., Prinzi, N., Colao, A., Faggiano, A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10040-x · Cited by 7

Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes of prostate cancer patients receiving gonadotropin-releasing hormone agonists

Tang, Z., Chang, Y.-C., Chi, K., Chang, Y., Lee, T.-N., Hsiao, C.-L., Chiang, C.-H., Wang, Q., Jang, A., & Chiang, C. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae267 · Cited by 5

Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology—a narrative review

Li, J., Qiao, J., Zhang, S., Zhong, J., Chen, K., Lin, Y. C., Li, Y., Jin, Y., Yao, Y., Zhai, A., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02749-3 · Cited by 7

Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin

Dong, W., Wang, Y., & Fan, S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04788-3 · Cited by 6

Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition

Kaijage, N., & Kraszewski, S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1668400 · Cited by 4

Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics

Garzon-Escamilla, N., Medina-Cardena, M., Roy, P., Trent, J., Jamous, J., Somesan, Y., & Denslow, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020316 · Cited by 5

Regulation of Iron-Ion Transporter SLC11A2 by Three Identical miRNAs

Sugino, Y., Uchiyama, R., Shibasaki, C., & Kugawa, F. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00214 · Cited by 4

From Hyperinsulinemia to Cancer Progression: How Diminishing Glucose Storage Capacity Fuels Insulin Resistance

Kareva, I. (2024) · Aging and Cancer · doi:10.1002/aac2.12073 · Cited by 5

Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial

Rosell, R., González‐Cao, M., & Molina‐Vila, M. Á. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00191-7 · Cited by 4

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies

Piras, L., Zuccanti, M., Tini, G., Volpe, M., Tocci, G., Barbato, E., & Battistoni, A. (2024) · Hearts · doi:10.3390/hearts5040039 · Cited by 4

Advances in sodium-glucose transporter protein 2 inhibitors and tumors

Wang, J., & Yang, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1522059 · Cited by 4

Metabolic Reprogramming and Molecular Rewiring in Cancer: Therapeutic Opportunities

Meiliana, A., Dewi, N. M., & Wijaya, A. (2021) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v13i2.1598 · Cited by 3

The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis

Reshadmanesh, T., Mohebi, R., Behnoush, A. H., Reshadmanesh, A., Khalaji, A., Norouzi, M., Javanmardi, E., Pishdad, R., Jafarzadeh, S. R., Ghondaghsaz, E., et al. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00343-4 · Cited by 3

Solute Carrier transporters in tumor metabolism and immune modulation: implications for therapy

Zhou, J., Wen, W., Xu, Y., Yu, J., & Chen, D. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07918-4 · Cited by 3

Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects

Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3

A microbial iron fist to fight tumors

Nobs, S. P., & Elinav, E. (2024) · Nature Immunology · doi:10.1038/s41590-024-01806-z · Cited by 3

Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C

Yang, W., Ge, J., Yuan, M., Li, J., Pan, L., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001428 · Cited by 3

Comparison between an SGLT2 inhibitor and insulin in tumor-to-tissue contrasts in 18F-FDG PET imaging of diabetic mice

Liang, M., Du, Y., Zhaoyu, L., Shanshi, L., Zhao, G., Fan, Y., Xiuying, Y., & Jianhua, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-45094-3 · Cited by 3

Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2

Lin, L., Zhong, S., Zhou, Y., Xia, J. L., Deng, S., Jiang, T., Jiang, A., Huang, Z., & Wang, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108907 · Cited by 3

Synthetic lethality targeting LKB1 mutant and EGFR wild type human non-small cell lung cancer cells by glucose starvation and SGLT2 inhibitionPreprint

Ren, Y., Chen, J., Mo, X., Yang, Q., Chen, P., Lu, G. X., Tan, H. W. S., Yi, J., Yu, Q., Kim, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622126 · Cited by 3

High glucose enhances lung cancer cell aggressiveness: the impacts of GLUT1, UAP1, UGP2, and N-linked glycosylation

Phoomak, C., Saengboonmee, C., Baro, M., Piriyapairoje, K., Ittiudomrak, T., Contessa, J. N., & Wongkham, S. (2025) · Glycobiology · doi:10.1093/glycob/cwaf089 · Cited by 2

Targeted metabolism creates possibilities for lung cancer treatment in the precision tumor era

Huang, X., Shen, H., Shao, C., Wang, L., Zheng, X., Wang, Y., Qiu, L., Zhang, S., Zhang, T., & Lu, Z. (2026) · Respiratory Research · doi:10.1186/s12931-025-03383-7 · Cited by 2

Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules

Tu, M., Wang, X., Liu, H., Jia, H., Wang, Y., Li, J., & Zhang, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-73542-1 · Cited by 2

Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis of randomized controlled trials

Wang, Y., Li, Z., Lin, C., Zhou, J., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2439970 · Cited by 2

Personalizing Heart Failure Care to the Patient With Cancer

Lambrinou, E., DeCourcey, J., & Hill, L. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-021-00536-9 · Cited by 2

MicroRNA-133a-3p Inhibits Lung Adenocarcinoma Development and Cisplatin Resistance through Targeting GINS4

Zhou, Y., Yan, J., Chen, H., Zhou, W., & Yang, J. (2022) · Cells Tissues Organs · doi:10.1159/000527684 · Cited by 2

A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions

Bossi, A. C., Forloni, F., & Colombelli, P. L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00943-6 · Cited by 2

Unified multimodal learning enables generalized cellular response prediction to diverse perturbationsPreprint

Li, C., Wei, L., & Zhang, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.688367 · Cited by 3

Prediction and analysis of the tumor invasiveness of pulmonary ground-glass nodules based on metabolomics

Liu, Z., Wang, L., Gao, S., Xue, Q., Tan, F., Li, Z., & Gao, Y. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01529-3 · Cited by 1

Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis

Ahmed, H., Gomaa, S., Razzak, I. A., Razzak, I. A., & Kovalovich, K. K. (2025) · Cureus · doi:10.7759/cureus.84768 · Cited by 4

Risk assessment and interventions for malignant ground-glass lung nodules

Ge, X., Hu, J., Li, Y., Wang, L., Luo, Y., Hua, B., & Liu, R. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104856 · Cited by 1

Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection

Li, S., Wang, Y., & Gong, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1641699 · Cited by 1

Canagliflozin synergises with serine restriction mediating anti-leukaemic effects in T-cell acute lymphoblastic leukaemia

Ponce-Garcia, F. M., Jenkins, Y. R., Assmann, V. D., Paul, S., Sharma, N. D., Moore, C., Ma, E. H., Diamanti, P., Hennequart, M., Blagih, J., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102275 · Cited by 1

Effect of treatment duration on the associations between three modern antidiabetic drugs and survival outcomes of lung cancer in China

Chen, Z., Wang, X. H., Zhang, Z., Lu, Y., Lei, C. Z., Di, Y., Huang, Y., & Li, Y. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1701515 · Cited by 1

Sodium-glucose cotransporter-specific substrate αMG stimulates endogenous glucagon secretion and ameliorates obesity-associated metabolic disorders in mice

Suga, T., Tabei, Y., Kikuchi, O., Kohno, D., Ikeuchi, Y., Kobayashi, M., Nakagawa, Y., Tojima, H., Yamazaki, Y., Sato, K., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102324 · Cited by 1

SGLT2 inhibitor use reduces progression and surgical intervention of persistent pulmonary nodules

Welch, K. O., McGovern, K. A., Chen, L., Welch, J. C., Krouse, R., Huang, J., Guo, K., Brown, M., Singhal, S., Hwang, W.-T., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109356 · Cited by 1

Unraveling the Potential of Empagliflozin to Counteract 1,2‐Dimethylhydrazine‐Induced Colorectal Cancer in Rats: Involvement of Redox Imbalance, Inflammatory Cascades, and Unprogrammed Cell Proliferation

Al‐Hamid, H. A., Mahmoud, M. O., El‐Ansary, M. R., Hassan, N. F., & Gomaa, S. B. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70886 · Cited by 1

Oxidative Stress in Cell Signaling and Cell Fate Determination Under Glucose Starvation

Ren, Y., Cheong, C., & Shen, H. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_13 · Cited by 1

Development of a selective novel fluorescent substrate for sodium-dependent transporters

Agnes, R. S., Traughber, B. J., & Muzic, R. F. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122847 · Cited by 1

Urinary biomarkers for lung cancer detection

Matov, A. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100456 · Cited by 1

Is cancer incidence modified by SGLT2 inhibitors?

Berstein, L. M. (2019) · Diabetes Mellitus · doi:10.14341/dm10119 · Cited by 1

Renal Specific RNAi Delivery by Fibrillar Nanoparticle Excipients

Wong, S. (2019) · CUNY Academic Works (City University of New York)

[Progress in the clinical application and correlation between glucose transporter-1 and 18F-FDG PET/CT imaging for non-small cell lung cancer].

Yang, M., & You, J. (2021) · PubMed Central · doi:10.7507/1001-5515.202010004

Computational Study of Novel Natural Inhibitors Targeting Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12CPreprint

Ge, J., Yuan, M., Lin, J., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., Wang, X., & Zhong, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1391554/v1

Glucose Deprivation Promotes Pseudo-Hypoxia and De-Differentiation in Lung Adenocarcinoma, Driving an Aggressive PhenotypePreprint

Saggese, P., Pandey, A., Fung, E., Yanagawa, J., Rodriguez, E. F., Grogan, T., Giurato, G., Nassa, G., Salvati, A., Weisz, A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4124636

Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes: a retrospective cohort studyPreprint

Shapiro, S. B., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · medRxiv · doi:10.1101/2022.08.09.22278566

Dapagliflozin improves the dysfunction of HUVECs by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2Preprint

Zhong, S., Xia, J. L., Jiang, T., Jiang, A., Huang, Z., & Wang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1958565/v1

Causal relationships between dietary habits and lung cancer: A two- sample Mendelian randomization studyPreprint

Gu, P., Zhu, Z., Tan, X., Deng, L., & Ma, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3930733/v1

Low SLCO4C1 expression serves as an independent prognostic predictor in lung cancerPreprint

Wen, L., Xie, L., Liu, Q., Zhang, S., Chen, Z., Hu, J., & Gong, F. (2024) · Research Square · doi:10.21203/rs.3.rs-3900353/v1

Research Progress of Sodium-Glucose Co-Transporter Protein-2 Inhibitors in Lung Cancer

林, 晓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14102810

A novel murine carcinogen-induced model recapitulates the progression and heterogeneity of human lung adenocarcinoma

Pandey, A., Gomez, E., Soto, A., Alcaraz, M., Jaldu, S., Quezada, F., Dumitras, C., Saggese, P., Liu, B., Fishbein, G. A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108581

Antidiabetic agents as potential cytotoxic candidates for cancer therapy

Alnaser, R. I., Alassaf, F. A., & Abed, M. N. (2024) · Forum of Clinical Oncology · doi:10.2478/fco-2023-0041 · Cited by 1

Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential

Zieliński, M., Michalak, O., Ruszczak, M., & Cybulski, M. (2025) · Molecules · doi:10.3390/molecules30244681

Additional file 1 of SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells

Anastasio, C., Donisi, I., Vecchio, V. D., Colloca, A., Mele, L. L., Sardu, C., Marfella, R., BALESTRIERI, M. L., & D’Onofrio, N. (2024) · Figshare · doi:10.6084/m9.figshare.25929059

Additional file 1 of Comparative immunological landscape between pre- and early-stage LUAD manifested as ground-glass nodules revealed by scRNA and scTCR integrated analysis

Wang, Z., Yang, L., Wang, W., Zhou, H., Chen, J., Ma, Z., Wang, X., Zhang, Q., Liu, H., Zhou, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24558144

Potential molecular mechanisms of malignant evolution in pulmonary nodules: From precancerous lesions to invasive adenocarcinoma

Lu, G., Li, Y., Liu, X., & Cui, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189529

The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes

Chen, J., Wang, H., Shang, C., Fan, Z., Sheng, Z., Chu, T., Zhang, M., & Zhao, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1759702

Developing a Metabolic-Associated Prognostic Index for Risk Stratification and Therapeutic Guidance in Stage I Lung Adenocarcinoma via Multiomics Analysis

Liu, P., Chen, Z., Hong, H., & Sun, Y. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00897

Safety and Efficacy of Sodium Glucose Cotransporter‐2 Inhibitors in Patients With Cancer and Diabetes

Perelman, M. G., Brzezinski, R. Y., Banai, S., Wolf, I., & Laufer‐Perl, M. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042404

The Role of Hepatocyte-Nuclear-Factor-1-A (HNF1A) in the Regulation of Glucose Homeostasis and Pancreatic Hormone Secretion

Acosta-Montalvo, A. (2022) · theses.fr (ABES) · doi:10.70675/3712a689zf56fz4ce7z814bz28dc25f0cc70

Translational development of an SGLT2-targeted near-infrared contrast agent for intraoperative imaging of early-stage lung cancer

Ortmeyer, K. A., McGovern, K. A., Tidwell, J. C., Shi, X., Chen, L., Krouse, R., Guo, K., Huang, J., Brown, M., Mlakar, J., et al. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01425-9

Dapagliflozin Mitigates Gamma Radiation-Induced Lung Injury in Rats Through Downregulation of Ferroptosis and Endoplasmic Reticulum Stress

Abdou, F. Y., Shibrya, E. E., Ali, M., Arafa, N. M., & Abdelaleem, R. M. A. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103438

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia

Yen, T., Lu, C. A., Hsieh, T. Y. J., Lee, G. Y., Jiang, C., & Tanner, E. J. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.06.023

SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy

Wang, Y., Zhang, E., Ma, R., Liu, W., Wang, Q., Zhang, J., Yinmo, Y., Ma, Y., & Tian, X. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01256-9

Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells

Buczyńska, A., Redlińska, J., Zając, J., Kościuszko, M., Adamska, A., Siewko, K., Popławska‐Kita, A., & Kretowski, A. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146131

Sodium‐Glucose Cotransporter 2 Inhibitors and Cancer Risk in Patients With Type 2 Diabetes Mellitus: An Active Comparator, New‐User Cohort Study

Li, Y., Zeng, H., Du, F., Wu, L., Ke, X., Li, P., Song, Y., Zhao, H., & Wang, S. (2026) · International Journal of Cancer · doi:10.1002/ijc.70642

Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells

Szachniewicz, M., Baran, M. H. H., Gagat, M., & Hałas‐Wiśniewska, M. (2026) · Biomedicines · doi:10.3390/biomedicines14092037

Repurposing SGLT2 Inhibitors Beyond Diabetes: Emerging Roles in Cancer Prevention and Therapy

Shrestha, A., Perez, I., Miles, J., Lopategui, L. C., Deb, S., & Basak, D. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_846

Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review

Shakour, N., Hosseini, F., Esmaeili, Z., & Hadizadeh, F. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101521

2394 Sodium-glucose transporter 2 is a novel diagnostic and therapeutic target for early-stage lung adenocarcinoma

Scafoglio, C., Abdelhady, G., Liu, J., Yanagawa, J., Wallace, D. W., Barrio, J., Dubinett, S. M., & Shackelford, D. B. (2018) · Journal of Clinical and Translational Science · doi:10.1017/cts.2018.122 · Cited by 1

Abstract 4224: SGLT2 is a diagnostic target for early stage lung adenocarcinoma

Villegas, B., Koziolek, E. J., Liu, J., Wallace, W. D., Elashoff, D. A., Aberle, D. R., Shackelford, D. B., Barrio, J. R., Yanagawa, J., Dubinett, S. M., et al. (2019) · Prevention, Early Detection, and Interception · doi:10.1158/1538-7445.sabcs18-4224

Abstract A16: Sodium-dependent glucose transporter 2 is a novel diagnostic and therapeutic target for early-stage lung adenocarcinoma

Scafoglio, C., Bailey, S. T., Abdelhady, G., Liu, J., Yanagawa, J., Shirali, A. S., Wallace, D. W., Barrio, J. R., Wright, E. M., Walser, T. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1557-3265.aacriaslc18-a16

P1.11-14 SGLT2 Is a Diagnostic and Therapeutic Target for Early-Stage Lung Adenocarcinoma

Villegas, B., Koziolek, E. J., Liu, J., Barrio, J. R., Wallace, W. D., Elashoff, D. A., Aberle, D. R., Yanagawa, J., Shackelford, D. B., Dubinett, S. M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.1087

Repurposing SGLT2 inhibitors

Crunkhorn, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.229 · Cited by 9